

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**INSIDE INFORMATION ANNOUNCEMENT**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the Incident disclosed in the inside information announcement of the Company dated 15 January 2024 and 30 January 2024.

The Company’s wholly-owned subsidiary, Techdow Pharma Italy S.R.L. (hereinafter referred to as “**Techdow Italy**”), was defrauded by a criminal syndicate as a result of telecom fraud, involving an amount of approximately 11.7 million euros. In order to safeguard the interests of the Company and its many investors, on 3 February 2024, Mr. Li Li, the controlling shareholder of the Company (“**Mr. Li**”), committed to advance funds in RMB equivalent to no more than 11.74 million euros to the Company. For details, please refer to the overseas regulatory announcement of the Company dated 3 February 2024 regarding the rectification report on the decision of CSRC Shenzhen Regulatory Bureau to order corrective measures for the Company.

On 14 March 2024, the Company received funds advanced by Mr. Li, through Shenzhen Leren Technology Co., Ltd. (“**Shenzhen Leren**”), amounting to RMB89,809,600 (calculated based on the average exchange rate of 1 euro to RMB7.6500, which was used by the Company to determine the non-operating losses as of 31 December 2023, involving an amount of 11,739,817 euros).

The Company hereby confirms that if the Company or its affiliates (including but not limited to Techdow Italy) recovers all or part of the payments or obtains any compensation of any nature from any relevant liable party through criminal, civil or other legal proceedings or by any other means, after such payments or compensation are recovered or obtained, the Company shall return to Shenzhen Leren the equivalent of the abovementioned amount in RMB, calculated at a fixed exchange rate of 1 euro to RMB7.6500, and the total returned amount shall not exceed the total amount of the payments actually advanced by Shenzhen Leren to the Company, and no interest of any form shall accrue on such advance payments during the relevant period.

**Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, the PRC  
March 15, 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.*